Market revenue in 2023 | USD 619.5 million |
Market revenue in 2030 | USD 336.4 million |
Growth rate | -8.4% (CAGR from 2023 to 2030) |
Largest segment | Conventional pcr |
Fastest growing segment | Conventional PCR |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Conventional PCR |
Key market players worldwide | Thermo Fisher Scientific Inc, Danaher Corp, Abbott Laboratories, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Qiagen NV, Roche Holding AG ADR, Standard BioTools Inc, Stilla, Microsynth |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to polymerase chain reaction market will help companies and investors design strategic landscapes.
Conventional pcr was the largest segment with a revenue share of 4.79% in 2023. Horizon Databook has segmented the Spain polymerase chain reaction market based on conventional pcr covering the revenue growth of each sub-segment from 2018 to 2030.
Rising prevalence of chronic diseases in Spain, such as cancer, is expected to be the key factor propelling market growth. According to World Cancer Research Fund (WCRF) International, in 2020, around 260,455 newly diagnosed cancer cases were recorded in the country.
It is estimated that the number of cancer cases is likely to rise due to increasing life expectancy in the country. The rise in chronic diseases, coupled with the increasing awareness regarding the early diagnosis, is expected to propel the use of PCR technologies. The outbreak of COVID-19 also increased the demand for qPCR products for diagnostic purposes.
To address the rising demand, local players developed and introduced new products. For instance, in March 2020, GENOMICA SAU, a Spanish company of PharmaMar Group, received CE certification for CLART COVID-19. The product is a real-time multiplex RT-PCR test kit validated at Carlos III Health Institute with 100% diagnostic specificity.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain polymerase chain reaction market , including forecasts for subscribers. This country databook contains high-level insights into Spain polymerase chain reaction market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account